Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer

Figure 2

Principal component analysis (PCA) score plot of metabolic profile of early-stage NSCLC, LBD, and HC after mean-centering and not (Ctr) scaling ((a): NSCLC versus HC, R²X=0.560; (b) NSCLC versus LBD, R²X=0.531; (c) LBD versus HC, R²X=0.514). Purple dot, orange diamond, and red triangle denote early-stage NSCLC, HC, and LBD samples, respectively. NSCLC, non-small cell lung cancer; LBD, lung benign disease; HC, healthy controls.

(a)

(b)

(c)